Overview of Gefitinib in Non-small Cell Lung Cancer: An Asian Perspective

被引:64
作者
Jiang, Haiyi [1 ]
机构
[1] AstraZeneca KK, Osaka, Japan
关键词
non-small cell lung cancer; gefitinib; Asian patients; EGFR mutations; GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITOR; PHASE-II TRIAL; SINGLE-AGENT GEFITINIB; CHEMOTHERAPY-NAIVE PATIENTS; PREVIOUSLY TREATED PATIENTS; JAPANESE PATIENTS; EGFR MUTATIONS; 1ST-LINE THERAPY; GENE-MUTATIONS;
D O I
10.1093/jjco/hyn139
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Clinical experience with the EGFR-TKI gefitinib in Asian patients with NSCLC will be reviewed, both in patients who have previously failed chemotherapy and in the first-line setting (gefitinib is currently not licensed for first-line treatment). Tolerability and specific adverse events in patients of Asian origin will be discussed. Differing objective response rates between patients of Asian and non-Asian origin when treated with gefitinib (and standard cytotoxics) will also be discussed along with EGFR mutations and drug resistance. Reports of Phase II/III clinical experience with gefitinib 250 mg/day in Asia were identified by searching in Medline and ASCO databases for publications between 1993 and 2008. Defined search criteria included (gefitinib OR Iressa OR ZD1839) AND NSCLC AND (Asia OR Japan OR China OR Taiwan OR Korea) or 'Clinical trial' type, with additional searches, including AND 'interstitial lung disease (ILD)' or 'EGFR mutation'. Numerous Phase II/III trials including patients of Asian origin with previously treated advanced NSCLC report a consistent clinical benefit of gefitinib. Gefitinib is generally well tolerated by patients with NSCLC although the incidence of ILD in Japanese patients must be noted. Studies analyzing EGFR mutations indicate that these mutations occur at a much higher rate in patients of Asian origin than in non-Asian patients. Data from several studies indicate that EGFR mutation-positive patients of Asian origin have better efficacy outcomes with first-line gefitinib when compared with those who are EGFR mutation-negative. Research is ongoing to evaluate the role of tailoring patients' treatment according to their genetic phenotype.
引用
收藏
页码:137 / 150
页数:14
相关论文
共 98 条
[1]   A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion [J].
Adiseshaiah, Pavan ;
Vaz, Michelle ;
Machireddy, Narsa ;
Kalvakolanu, Dhananjaya V. ;
Reddy, Sekhar P. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2008, 216 (02) :405-412
[2]   Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib [J].
Ando, M ;
Okamoto, I ;
Yamamoto, N ;
Takeda, K ;
Tamura, K ;
Seto, T ;
Ariyoshi, Y ;
Fukuoka, M .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2549-2556
[3]  
[Anonymous], ANN ONCOL S8
[4]   Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer [J].
Argiris, A ;
Mittal, N .
LUNG CANCER, 2004, 43 (03) :317-322
[5]   Gefitinib in advanced non-small cell lung cancer: Clinical experience in patients of Asian origin [J].
Armour, Alison .
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2007, 3 (02) :66-78
[6]   A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations [J].
Asahina, H. ;
Yamazaki, K. ;
Kinoshita, I. ;
Sukoh, N. ;
Harada, M. ;
Yokouchi, H. ;
Ishida, T. ;
Ogura, S. ;
Kojima, T. ;
Okamoto, Y. ;
Fujita, Y. ;
Dosaka-Akita, H. ;
Isobe, H. ;
Nishimura, M. .
BRITISH JOURNAL OF CANCER, 2006, 95 (08) :998-1004
[7]   Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].
Baselga, J ;
Rischin, D ;
Ranson, M ;
Calvert, H ;
Raymond, E ;
Kieback, DG ;
Kaye, SB ;
Gianni, L ;
Harris, A ;
Bjork, T ;
Averbuch, SD ;
Feyereislova, A ;
Swaisland, H ;
Rojo, F ;
Albanell, J .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302
[8]   Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations:: Analysis of estrogen-related polymorphisms [J].
Bell, Daphne W. ;
Brannigan, Brian W. ;
Matsu, Keitaro ;
Finkelstein, Dianne M. ;
Sordella, Raffaella ;
Settleman, Jeff ;
Mitsudomi, Tetsuya ;
Haber, Daniel A. .
CLINICAL CANCER RESEARCH, 2008, 14 (13) :4079-4084
[9]   Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors [J].
Calvo, Emiliano ;
Baselga, Jose .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (14) :2158-2163
[10]   Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study [J].
Chang, Alex ;
Parikh, Purvish ;
Thongprasert, Sumitra ;
Tan, Eng Huat ;
Perng, Reury- Perng ;
Ganzon, Domingo ;
Yang, Chih-Hsin ;
Tsao, Chao-Jung ;
Watkins, Claire ;
Botwood, Nick ;
Thatcher, Nick .
JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (08) :847-855